Table 1.
Demographic and clinical characteristics overall and by molecular classification and L1CAM status
| dMMR (N = 41) |
MMR-proficient | Total (N = 155) |
p value | |||
|---|---|---|---|---|---|---|
| p53wt/pMMR -L1CAM(-) (N = 41) |
p53wt/pMMR -L1CAM( +) (N = 20) |
p53abn (N = 53) |
||||
| Age(years) | ||||||
| Mean (SD) | 51.7(± 9.5) | 55.6(± 10.7) | 60.1(± 9.4) | 59.6(± 10.7) | 56.5(± 10.7) | 0.001 |
| BMI | ||||||
| Mean (SD) | 23.7(± 4.5) | 25.4(± 4.0) | 23.5(± 3.9) | 25.2(± 5.3) | 24.6(± 4.6) | 0.201 |
| Parity | ||||||
| 0 | 17(41.5%) | 11(26.8%) | 6(30.0%) | 10(18.9%) | 44(28.4%) | 0.117 |
| 1 or more | 24(58.5%) | 30(73.2%) | 14(70.0%) | 43(81.1%) | 111(71.6%) | |
| Diabetes | ||||||
| No | 35(85.4%) | 33(80.5%) | 17(85.0%) | 46(86.8%) | 131(84.5%) | 0.863 |
| Yes | 6(14.6%) | 8(19.5%) | 3(15.0%) | 7(13.2%) | 24(15.5%) | |
| Prior malignancies | ||||||
| No | 38(92.7%) | 41(100.0%) | 19(95.0%) | 45(84.9%) | 143(92.3%) | 0.053 |
| Yes | 3(7.3%) | 0(0.0%) | 1(5.0%) | 8(15.1%) | 12(7.7%) | |
| CA-125 at diagnosis | ||||||
| Mean (SD) | 130.4(± 24.0) | 95.5(± 184.3) | 59.1(± 67.6) | 154.0(± 307.2) | 120.0(± 220.1) | 0.338 |
| Histology | ||||||
| Endometrioid | 37(90.2%) | 34(82.9%) | 15(75.0%) | 27(50.9%) | 113(72.9%) | 0.002 |
| Serous | 0(0.0%) | 2(4.9%) | 1(5.0%) | 10(18.9%) | 13(8.4%) | |
| Clear cell | 2(4.9%) | 1(2.4%) | 1(5.0%) | 4(7.5%) | 8(5.2%) | |
| MMMT | 1(2.4%) | 2(4.9%) | 1(5.0%) | 11(20.8%) | 15(9.7%) | |
| Adenocarcinoma | 0(0.0%) | 2(4.9%) | 2(10.0%) | 1(1.9%) | 5(3.2%) | |
| Neuroendocrine | 1(2.4%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(0.6%) | |
| Stage at diagnosis | ||||||
| III | 28(68.3%) | 27(65.9%) | 12(60.0%) | 28(52.8%) | 95(61.3%) | 0.457 |
| IV | 7(17.1%) | 4(9.8%) | 5(25.0%) | 13(24.5%) | 29(18.7%) | |
| Recur | 6(14.6%) | 10(24.4%) | 3(15.0%) | 12(22.6%) | 31(20.0%) | |
| Staging op pathological grade | ||||||
| 1 | 7(17.1%) | 12(29.3%) | 3(15.0%) | 0(0.0%) | 22(14.2%) | < 0.001 |
| 2 | 24(58.5%) | 19(46.3%) | 6(30.0%) | 14(26.4%) | 63(40.6%) | |
| 3 | 9(22.0%) | 9(22.0%) | 10(50.0%) | 39(73.6%) | 67(43.2%) | |
| none | 1(2.4%) | 1(2.4%) | 1(5.0%) | 0(0.0%) | 3(1.9%) | |
| Staging op LVSI | ||||||
| No | 15(36.6%) | 22(53.7%) | 7(35.0%) | 19(35.8%) | 63(40.6%) | 0.055 |
| Yes | 25(61.0%) | 19(46.3%) | 11(55.0%) | 34(64.2%) | 89(57.4%) | |
| Missing | 1(2.4%) | 0(0.0%) | 2(10.0%) | 0(0.0%) | 3(1.9%) | |
| Radiotherapy | ||||||
| No | 16(39.0%) | 27(65.9%) | 11(55.0%) | 34(64.2%) | 88(56.8%) | 0.049 |
| Yes | 25(61.0%) | 14(34.1%) | 9(45.0%) | 19(35.8%) | 67(43.2%) | |
Recur Recurrent endometrial cancer, dMMR Mismatch repair protein deficiency, p53wt/pMMR p53-wild with proficient mismatch repair, p53abn abnormal p53, BMI Body mass index, MMMT Malignant mixed Müllerian tumour, LVSI Lymph-vascular space invasion